{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.27","upperLimit":"52.71","value":"25"},{"groupId":"OG001","lowerLimit":"11.11","upperLimit":"59.97","value":"38"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"description":"To assess the efficacy of cobimetinib in patients with newly diagnosed and HMA- refractory chronic myelomonocytic leukemia (CMML). Overall response rate (ORR) is defined as the proportion of patients achieving complete remission, complete cytogenetic remission, partial remission, marrow response, and clinical benefit according to the 2015 MDS/MPN-IWG criteria.\n\nThis was assessed from the dose of study medication to the decision to end treatment, up to 20 months.","dispersionType":"90% Confidence Interval","groups":[{"description":"Patients treated with hypomethylating agent (HMA) refractory chronic myelomonocytic leukemia (CMML; 2022 WHO classification) with RAS pathway activation.\n\nExperimental: Treatment: All Patients Cobimetinib is taken on a 28-day cycle. Each dose consists of three 20 mg tablets (60 mg) and should be taken once daily for 21 consecutive days (Days 1 to 21-treatment period); followed by a 7-day break (Days 22 to 28-treatment break). Each subsequent cobimetinib treatment cycle should start after a 7-day treatment break has elapsed.","id":"OG000","title":"HMA Refractory"},{"description":"Patients with newly diagnosed chronic myelomonocytic leukemia (CMML; 2022 WHO classification) with RAS pathway activation.\n\nExperimental: Treatment: All Patients Cobimetinib is taken on a 28-day cycle. Each dose consists of three 20 mg tablets (60 mg) and should be taken once daily for 21 consecutive days (Days 1 to 21-treatment period); followed by a 7-day break (Days 22 to 28-treatment break). Each subsequent cobimetinib treatment cycle should start after a 7-day treatment break has elapsed.","id":"OG001","title":"Newly Diagnosed"}],"paramType":"NUMBER","populationDescription":"The EOT disease assessment was not done for one patient in error. One patient was not able to travel to the study site for the EOT disease assessment due to illness.","reportingStatus":"POSTED","timeFrame":"From the start of study treatment to the last dose of study treatment, up to 20 months","title":"Overall Response Rate (ORR)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}